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ABSTRACT
Objectives  This phase III study evaluated the efﬁ  cacy 
and safety of rituximab plus methotrexate (MTX) in 
patients with active rheumatoid arthritis (RA) who had an 
inadequate response to MTX and who were naïve to prior 
biological treatment.
Methods  Patients with active disease on stable 
MTX (10–25 mg/week) were randomised to rituximab 
2×500 mg (n=168), rituximab 2×1000 mg (n=172), 
or placebo (n=172). From week 24, patients not in 
remission (Disease Activity Score (28 joints) ≥2.6) 
received a second course of rituximab; patients initially 
assigned to placebo switched to rituximab 2×500 mg. 
The primary end point was American College of 
Rheumatology 20 (ACR20) response at week 24. All 
patients were followed until week 48.
Results  At week 24, both doses of rituximab showed 
statistically superior efﬁ  cacy (p<0.0001) to placebo 
(ACR20: 54%, 51% and 23%; rituximab (2×500 mg) 
+ MTX, rituximab (2×1000 mg) + MTX and placebo 
+ MTX, respectively). Secondary end points were also 
signiﬁ  cantly improved for both rituximab groups compared 
with placebo. Further improvements in both rituximab 
arms were observed from week 24 to week 48. Rituximab 
+ MTX was well tolerated, demonstrating comparable 
safety to placebo + MTX through to week 24, and 
between rituximab doses through to week 48.
Conclusions  Rituximab (at 2×500 mg and 2×1000 
mg) plus MTX signiﬁ  cantly improved clinical outcomes at 
week 24, which were further improved by week 48. No 
signiﬁ  cant differences in either clinical or safety outcomes 
were apparent between the rituximab doses.
INTRODUCTION
Rituximab, a monoclonal antibody against CD20 
that selectively targets B cells, has demonstrated 
signiﬁ  cant efﬁ  cacy with good tolerability in clini-
cal trials conducted in patients with active rheu-
matoid arthritis (RA).1 2 Rituximab 2×1000 mg 
plus methotrexate (MTX) signiﬁ  cantly improved 
clinical disease symptoms in patients with 
an intolerance or an inadequate response to 
tumour necrosis factor (TNF) inhibitors.2 In 
patients with an inadequate response to disease-
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modifying antirheumatic drugs (DMARDs), doses 
of 2×500 mg and 2×1000 mg of rituximab have 
shown clinical beneﬁ  t.3 Limited information sug-
gested that the 2×1000 mg dose was associated 
with higher levels of response.
This study further investigated the efﬁ  cacy and 
safety of rituximab 2×500 mg and 2×1000 mg in 
combination with MTX, in patients with active 
RA who had an inadequate response to MTX and 
in whom no prior biological treatment for RA had 
been administered. Maintenance of response and 
long-term safety following retreatment with ritux-
imab were explored.
METHODS
This was a multicentre, randomised, double-blind, 
placebo-controlled, phase III study conducted 
at 102 centres in 11 countries. Eligible patients 
were aged 18–80 years with RA   according to 
American College of Rheumatology (ACR) crite-
ria for ≥6 months, which was active despite MTX 
(10−25 mg/week for at least 12 weeks). Active 
disease was deﬁ  ned as swollen joint count (SJC) 
and tender joint count (TJC) both ≥8, and either 
C reactive protein (CRP) ≥0.6 mg/dl or erythro-
cyte sedimentation rate (ESR) ≥28 mm/h. Patients 
also had to have an absolute neutrophil count 
≥1500 cells/μl, a haemoglobin level ≥8 g/dl and 
IgM and IgG levels of ≥40 and ≥500 mg/dl, respec-
tively. Patients had not previously received bio-
logical treatment for RA.
The study was performed in accordance with 
the Declaration of Helsinki. All participating sites 
received approval from their governing institu-
tional review board (or equivalent) and all patients 
provided written informed consent.
Treatments
All patients underwent at least a 2-week wash-
out for all DMARDs (leﬂ  unomide ≥8 weeks or 
≥14 days after cholestyramine or activated char-
coal washout), but continued to receive con-
comitant MTX (10−25 mg/week) at a stable dose 
together with folic acid ≥5 mg/week or equiva-
lent. Stable dose oral corticosteroids (≤10 mg/day 
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prednisolone or equivalent) and non-steroidal anti-inﬂ  amma-
tory drugs were permitted.
Patients were randomised (1:1:1) to one of three treatment 
groups: rituximab 2×500 mg, rituximab 2×1000 mg, or placebo 
administered by intravenous infusion on days 1 and 15. All infu-
sions (including placebo) were premedicated with intravenous 
methylprednisolone 100 mg.
Between week 16 and week 23, patients with <20% improve-
ment in TJC and SJC versus baseline were allowed rescue treat-
ment with one non-biological DMARD, which was continued 
for the remainder of the study.
Repeat courses of open-label rituximab were scheduled 
from week 24. Eligible patients were those not in remission, 
(Disease Activity Score (DAS28-ESR) ≥2.6), who also met pre-
deﬁ  ned safety criteria (neutrophil count >1500 cells/μl). Patients 
were retreated with their randomised dose of   rituximab or, if 
initially assigned to placebo, switched to receive rituximab 
(2×500 mg).
Assessments
Clinical efﬁ   cacy assessments including ACR core set,4 were 
assessed at baseline and at either 4-week or 8-week intervals 
to week 48. The Functional Assessment of Chronic Illness 
Therapy-Fatigue (FACIT-F) was assessed at baseline and weeks 
12, 24 and 48; the Medical Outcomes Study 36-item Short Form 
Health Survey (SF-36) was assessed at baseline, week 24 and 
week 48.
Laboratory assessments included peripheral B cells, Igs and 
human anti-chimaeric antibodies (HACA) to rituximab.
Adverse events (AEs) and serious AEs were recorded through-
out the study and rates were calculated. Rates of infections and 
serious infections per 100 patient-years were calculated.
Clinical outcome measures
The primary end point was the proportion of patients with an 
ACR20 response at week 24. Secondary end points at week 24 
included proportions of patients achieving ACR50/70, European 
League Against Rheumatism (EULAR) responses, DAS28-ESR 
(mean change, low disease activity (LDA ≤3.2) and remission 
(<2.6)), Health Assessment Questionnaire Disability Index 
(HAQ-DI) (mean change, proportion of patients achieving a 
minimal clinically important   difference (MCID; improvement 
of ≥0.22)),5 SF-36 (mean change   summary scores, proportion 
of patients achieving the mental and physical component score 
MCIDs (6.33 and 5.42, respectively))6 7 and FACIT-F assess-
ment.8 Comparisons were made between the rituximab + MTX 
groups versus placebo + MTX.
At week 48 the proportions of patients achieving ACR50 and 
ACR70 responses, DAS28-ESR LDA and remission, and EULAR 
responses were compared between rituximab dose groups.
Sample size estimation
A target sample size of 167 patients per arm was estimated to 
provide at least 90% power to detect differences in the propor-
tions of patients with an ACR20 response at week 24 between 
each rituximab group versus placebo + MTX, using Fisher’s 
exact test, adjusting for multiplicity with a two-sided signiﬁ  -
cance level of p<0.025 for each test.
Statistical analysis
The efﬁ  cacy of rituximab versus placebo was analysed using 
the Cochran–Mantel–Haenszel test for categorical end points 
and analysis of variance (ANOVA) for continuous end points, 
adjusting for baseline stratiﬁ  cation factors of rheumatoid factor 
(RF) status and region (USA vs non-USA). ANOVA models also 
included the end point’s baseline value, if applicable.
Missing data, including data for patients who withdrew or 
received rescue treatment, were imputed using the non-re-
sponder method for ACR and EULAR and last observation car-
ried forward (LOCF) for all other end points.
The intention-to-treat (ITT) and safety populations were 
deﬁ  ned as all patients who were randomised and received any 
part of an infusion of study medication.
RESULTS
A total of 511 patients were randomised; 509 received at least 
1 infusion (ITT population). Over 90% of patients completed 
48 weeks of the study (table 1).
Demographic and baseline disease characteristics were well 
balanced across the three groups (table 2). Patients had a mean 
disease duration of approximately 7 years, with high disease 
activity (mean DAS28-ESR 6.40–6.54).
Clinical outcomes
Week 24 (placebo-controlled period)
At week 24, a signiﬁ  cantly greater proportion of patients receiving 
rituximab 2×500 mg or 2×1000 mg + MTX achieved an ACR20 
response versus patients receiving placebo + MTX (54.5% and 
50.6% vs 23.3%, respectively; p<0.0001) (ﬁ  gure 1). Signiﬁ  cantly 
greater proportions of patients receiving rituximab 2×500 mg or 
2×1000 mg + MTX also achieved ACR50 versus those receiv-
ing placebo + MTX (26.3% and 25.9% vs 9.3%, respectively; 
p<0.0001) (ﬁ   gure 1). ACR70 responses were achieved by a 
greater proportion of patients receiving either dose of rituximab 
+ MTX versus those receiving placebo + MTX, although the dif-
ferences did not achieve statistical signiﬁ  cance (ﬁ  gure 1).
For both rituximab + MTX dose groups there were signiﬁ  -
cantly greater mean decreases in all individual components of 
the ACR core set (p≤0.0007), and signiﬁ   cantly greater mean 
changes in DAS28-ESR (p<0.0001) versus the placebo + MTX 
group. Signiﬁ   cantly higher proportions of patients receiving 
rituximab + MTX achieved EULAR responses, LDA and remis-
sion than placebo + MTX patients (p<0.05) (table 3).
Both rituximab doses produced statistically signiﬁ  cant 
improvements in patient-reported outcomes as demonstrated 
by changes in HAQ-DI, FACIT-F and SF-36 scores (table 3). 
Higher proportions of patients receiving rituximab + MTX also 
achieved MCIDs for HAQ and SF-36 subscales (table 3).
Week 48 (including second course of rituximab)
By week 48 approximately 90% of patients in all treatment 
groups had received a second course of treatment. The majority 
of these repeat treatments (82% to 88%) were given by week 
30.
Mean DAS28-ESR scores over the 48-week period for all 
treatment arms are presented in ﬁ  gure 2 and show maintained 
or improved levels of disease activity throughout the 48-week 
period with both doses of rituximab + MTX. Mean changes in 
DAS at week 48 were greater than at week 24 for both rituximab 
dose groups (table 3). At week 48, clinical responses (ACR and 
EULAR responses) were maintained in both rituximab groups 
versus week 24, with the majority of end points showing some 
improvement (ﬁ  gure 1 and table 3). Comparisons between the 
rituximab doses at week 48 did not identify signiﬁ  cant differ-
ences for any clinical end point.
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responses were generally higher in patients who were seroposi-
tive. Notably for high-hurdle end points, in patients receiving 
rituximab 2×1000 mg + MTX, ACR50 and ACR70 were 35% 
and 15% for patients who were seropositive versus 21% and 
0% for patients who were seronegative (data not shown).
Immunological outcomes
Receipt of rituximab was associated with characteristic  depletion 
of peripheral CD19+ cells, which was comparable between both 
rituximab doses.
Subgroup analyses
At week 24, a consistent treatment effect for both rituximab 
groups versus placebo was observed for ACR, EULAR and 
DAS28-ESR responses in medically important subgroups, 
including baseline seropositivity (either RF or anti-cyclic citrulli-
nated peptide (anti-CCP) antibody), duration of RA and baseline 
DAS28-ESR. However, in patients receiving rituximab, there 
were generally greater falls in DAS28-ESR over time in patients 
who were seropositive (n=144) compared with patients who 
were seronegative (n=24) (supplementary ﬁ  gure 1). At week 48, 
Table 1  Disposition of patients up to week 48
Patients, n (%) Placebo + MTX
Rituximab 2×500 mg 
+ MTX
Rituximab 2×1000 mg 
+ MTX
Randomised* 172 (100) 168 (100) 172 (100)
Treated (ﬁ  rst course)† 172 (100) 167 (99.4) 170 (98.8)
Completed 24 weeks (placebo-controlled period) 159 (92.4) 162 (96.4) 166 (96.5)
Retreated (second course) 154 (89.5) 152 (90.5) 154 (89.5)
Received rescue treatment post week 24   16 (9.3%)     6 (3.6%)   4 (2.3%)
  Leﬂ   unomide  (n)   5   1  1
  Hydroxychloroquine  (n)   4   2  –
  Sulfasalazine  (n)   3   1  3
  Cyclophosphamide  (n)   1   –  –
  Ciclosporin  (n)   3   2  –
Completed 48 weeks (second course of rituximab) 154 (89.5) 157 (93.5) 157 (91.3)
Withdrew before week 24   13 (7.6)     6 (3.6)     6 (3.5)
AE/intercurrent  illness   2  (1.2)   2  (1.2)   3  (1.7)
RA  ﬂ   are   7  (4.1)   1  (0.6)   0
Failure  to  return   1  (0.6)   1  (0.6)   3  (1.7)
Violation of selection criteria at entry     0     1 (0.6)     0
Withdrew  consent   3  (1.7)   0   0
Administrative/other   0   1  (0.6)   0
Withdrew before week 48   18 (10.5)   11 (6.5)   15 (8.7)
AE/intercurrent  illness   3  (1.7)   3  (1.8)   7  (4.1)
Death   0   2  (1.2)   0
RA  ﬂ   are  11  (6.4)   2  (1.2)   0
Failure  to  return   1  (0.6)   2  (1.2)   4  (2.3)
Violation of selection criteria at entry     0     1 (0.6)     0
Refused  treatment/did  not  cooperate   0   0   1  (0.6)
Withdrew  consent   3  (1.7)   0   1  (0.6)
Administrative/other   0   1  (0.6)   2  (1.2)
*Although 512 patients are listed, 1 patient was randomised twice. The actual number of randomised patients is 511.
†Intention-to-treat and safety populations.
AE, adverse event; MTX, methotrexate; RA, rheumatoid arthritis.
Table 2  Demographics and baseline disease characteristics
Characteristic Placebo + MTX (n=172)
Rituximab 2×500 mg + 
MTX (n=167)
Rituximab 2×1000 mg + 
MTX (n=170)
Mean (SD) age, years 52.16 (12.390) 51.91 (12.926) 51.30 (12.644)
Female, n (%) 147 (85.5) 133 (79.6) 138 (81.2)
Caucasian, n (%) 142 (82.6) 134 (80.2) 137 (80.6)
Mean (SD) disease duration, years 7.48 (7.642) 7.10 (6.969) 6.61 (7.294)
Mean (SD) MTX dose, mg/week 16.6 (4.30) 15.4 (4.02) 16.1 (4.25)
Mean (SD) number of previous DMARDs* 1.1 (1.10) 1.2 (1.25) 1.1 (1.11)
Patients receiving oral steroids, n (%) 82 (47.7) 80 (47.9) 67 (39.4)
Mean (SD) OCS dose, mg/day 6.3 (2.68) 5.8 (2.52) 6.1 (2.58)
RF positive, n (%) 129 (75.0) 126 (75.4) 125 (73.5)
Mean (SD) total RF, IU/ml 264.1 (492.03) 307.2 (774.94) 288.1 (539.5)
Mean (SD) SJC (66 joints) 20.9 (11.26) 18.6 (9.62) 19.5 (10.32)
Mean (SD) TJC (68 joints) 30.2 (15.94) 27.1 (14.10) 28.7 (14.98)
Mean (SD) DAS28-ESR 6.54 (1.015) 6.40 (0.951) 6.49 (1.061)
Mean (SD) DAS28-CRP 5.95 (0.972) 5.81 (0.912) 5.86 (0.967)
*Excludes MTX.
CRP, C reactive protein; DAS28, Disease Activity Score (28 joints); DMARDs, disease-modifying antirheumatic drugs; ESR, erythrocyte 
sedimentation rate; MTX, methotrexate; OCS, oral corticosteroid; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint 
count.
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Mean IgA, IgG and IgM levels declined from baseline in all 
three study groups. The decrease up to week 24 was com-
parable for both rituximab doses and was greater than the 
decrease seen in the placebo group. At week 24 the proportion 
of patients with IgA, IgG and IgM levels below the laboratory 
lower limit of normal (LLN) were 1.9%, 1.9% and 6.4%, respec-
tively, in the rituximab 2×500 mg group; 2.6%, 1.3% and 6.6%, 
  respectively, in the rituximab 2×1000 mg group; and 1.4%, 0% 
and 0%, respectively, in the placebo group. Mean levels contin-
ued to decline following the second course of rituximab. In all 
study groups, despite the above noted declines, mean IgA, IgG 
and IgM levels remained within normal limits throughout the 
study. The greatest change from baseline occurred in IgM, with 
an approximate 20% mean decrease from baseline at week 24 
and 30% decrease by week 48, in both rituximab dose groups, 
with minimal changes to IgG and IgA. No serious infections 
occurred in patients receiving rituximab while Ig levels were 
below the LLN.
At baseline, all patients were HACA negative. At week 24, 
positive HACA titres were observed in 7.9%, 5.4% and 3.6% 
of patients receiving rituximab (2×500 mg) + MTX, rituximab 
(2×1000 mg) + MTX and placebo + MTX, respectively. There 
was no apparent correlation between development of HACA 
and increased risk of infusion-related reactions (IRRs) or loss of 
response to subsequent retreatment with rituximab.
Safety
Safety to week 24 (placebo-controlled period)
During the 24-week placebo-controlled period, the overall 
incidence of AEs, serious AEs and AEs leading to withdrawal 
was similar across all treatment groups (table 4), with the most 
common AEs being IRRs, RA ﬂ  ares, nasopharyngitis and upper 
respiratory tract infections.
IRRs occurred more frequently with the ﬁ  rst infusion of the 
ﬁ  rst course in all three treatment groups, than with the second 
infusion of the same course (table 4). The incidence of IRRs was 
highest in patients receiving a ﬁ  rst rituximab infusion of 1000 mg 
(25%) compared with a ﬁ  rst infusion of 500 mg rituximab or 
placebo (19% and 14%, respectively) (table 4). There were no 
serious IRRs reported during the initial treatment although one 
patient receiving rituximab 2×1000 mg withdrew due to an IRR 
Figure 1  American College of Rheumatology (ACR) 20/50/70 
responses at week 24 and week 48 in patients receiving placebo 
(n=172), rituximab 2×500 mg (n=167) or rituximab 2×1000 mg 
(n=170) (all plus a stable dose of methotrexate 10−25 mg/week), 
non-responder imputation (intention-to-treat population). ***p≤0.0001 
vs placebo.
Table 3  Summary of disease-activity and quality-of-life clinical end points for patients treated with placebo vs rituximab 2×500 mg and 
2×1000 mg (all plus a stable dose of methotrexate (MTX) 10−25 mg/week) at week 24 and week 48 (intention-to-treat population)
Clinical end point
Week 24 Week 48
Placebo + 
MTX (n=172)
Rituximab 2×500 mg + 
MTX (n=167)
Rituximab 2×1000 mg + 
MTX (n=170)
Rituximab 2×500 mg + 
MTX (n=167)
Rituximab 
2×1000 mg + 
MTX (n=170)
Adjusted mean change in DAS28-ESR score from baseline† –0.75 –1.76*** –1.69*** –1.96 –2.02
EULAR response, n (%)
  Moderate 50 (29.1) 82 (49.1)*** 87 (51.2)*** 89 (53.3)   81 (47.6)
  Good 8 (4.7) 29 (17.4)*** 20 (11.8)*** 33 (19.8)   35 (20.6)
DAS28-ESR end points, n (%)‡
 LDA  (DAS28-ESR  ≤3.2) 8 (4.7) 29 (17.5)** 21 (12.4)* 33 (20.0)   41 (24.3)
  Clinical remission (DAS28-ESR <2.6) 4 (2.3) 16 (9.6)** 16 (9.4)** 15 (9.1)   19 (11.2)
Clinically relevant HAQ-DI improvement, mean change from 
baseline ≥MCID of 0.22, n (%)§
82 (47.7) 109 (66.1)** 99 (58.2)** 121 (73.3) 117 (68.8)
FACIT-F change from baseline score¶
 Adjusted  mean 2.12 5.51** 6.53*** NA NA
SF-36 mean change from baseline††
  SF-36 summary score mean adjusted
   Mental  component 1.66 3.31 4.58** NA NA
   Physical  component 2.49 5.91*** 5.70*** NA NA
  Clinically relevant improvement in summary score (n (%))
   Mental  health  (≥MCID of 6.33) 35 (23.8) 51 (33.6) 54 (34.8)* NA NA
   Physical  health  (≥MCID of 5.42) 45 (30.6) 70 (46.1)** 75 (48.4)** NA NA
Missing data were imputed using non-responder imputation for EULAR and ACR20/50/70 and LOCF for DAS28-ESR, LDA, clinical remission and quality-of-life end points.
*p<0.05; **p<0.01; ***p≤0.0001 vs placebo.
†Negative change represents an improvement. Patient numbers for this assessment: week 24 placebo (n=171), rituximab 2×500 mg (n=166), rituximab 2×1000 mg (n=168).
‡Patient numbers for this assessment: week 24 rituximab 2×500 mg + MTX (n=166); week 48 rituximab 2×500 mg + MTX (n=165), rituximab 2×1000 mg + MTX (n=169).
§Patient numbers for this assessment: weeks 24 and 48 rituximab 2×500 mg (n=165).
¶Patient numbers for this assessment: week 24 placebo + MTX (n=170), rituximab 2×500 mg (n=165), rituximab 2×1000 mg (n=168).
††Patient numbers for this assessment: week 24 placebo + MTX (n=147), rituximab 2×500 mg (n=152), rituximab 2×1000 mg (n=155).
ACR, American College of Rheumatology; DAS28, Disease Activity Score (28 joints); ESR, erythrocyte sedimentation rate; EULAR, European League Against Rheumatism; FACIT-F, 
Functional Assessment of Chronic Illness Therapy-Fatigue; HAQ-DI, Health Assessment Questionnaire Disability Index; LDA, low disease activity; LOCF, last observation carried forward; 
MCID, minimum clinically important difference; NA, not available; SF-36, Medical Outcomes Study 36-item Short Form Health Survey.
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that occurred on day 1 of the ﬁ  rst course of treatment (dysp-
noea, laryngeal/throat irritation, nausea, pruritus, rash, throat 
itching and urticaria).
Over the initial 24-week period the rates of infection (all 
infections and serious infections) were lower in the rituximab + 
MTX arms compared with the placebo + MTX group (table 4). 
The overall rate of serious infections was 1.26 and 2.46 events 
per 100 patient-years for rituximab 2×500 mg and 2×1000 mg, 
respectively, compared with 8.83 events per 100 patient-years 
for placebo (table 4).
Four malignancies were reported during the 24-week 
  placebo-controlled period: one each in the placebo + MTX and 
rituximab (2×500 mg) + MTX groups (lung adenocarcinoma 
and squamous cell carcinoma of the cervix, respectively) and 
two in the rituximab (2×1000 mg) + MTX group (oesophageal 
adenocarcinoma and pancreatic carcinoma (fatal)) (table 4).
The incidence of other AEs including lower gastrointestinal 
events, cardiac events and vascular events was similar in the 
rituximab groups and placebo arm (table 4).
Safety to week 48 (including second course of rituximab)
Up to week 48, the overall safety proﬁ  le remained similar in the 
two rituximab groups (table 4).
The incidence of IRRs in those patients who received a sec-
ond course of rituximab was lower than that reported for the 
initial course, with 10% to 11% of patients experiencing an IRR 
irrespective of rituximab dose. As with the initial course there 
were no serious IRRs, although two patients receiving rituximab 
(2×1000 mg) + MTX withdrew due to IRRs that occurred dur-
ing their second course. One patient reported mild symptoms 
of headache, nausea and lethargy, whereas the second patient 
reported severe pruritus and rash and mild throat itching and 
diaphoresis.
The rates of infection, including serious infections, remained 
consistent with the rates observed over the initial 24 weeks 
Figure 2  Mean change from baseline in Disease Activity Score (28 
joints) erythrocyte sedimentation rate (DAS28-ESR) over time through to 
week 48, last observation carried forward imputation (intention-to-treat 
population). MTX, methotrexate.
Table 4  Overall safety of placebo and rituximab 2×500 mg and 2×1000 mg (all with a stable dose of methotrexate (MTX) 10−25 mg/week) over 
48 weeks (safety population)
 
Baseline to week 24 Baseline to week 48
Placebo + 
MTX (n=172)
Rituximab 2×500 mg + 
MTX (n=167)
Rituximab 2×1000 mg + 
MTX (n=170)
Rituximab 2×500 mg + 
MTX (n=167)
Rituximab 2×1000 mg + 
MTX (n=170)
Treated (n) 172 167 170 152 154
Total patient-years of follow-up 79.24 79.63 81.36 152.43 153.36
Patients with AEs, n (%)
  Any AE 128 (74) 128 (77) 130 (76) 143 (86) 138 (81)
 Deaths 0 0 0 2  (1) 0
  Deaths after withdrawal 1 (<1) 0 0 1 (<1) 1 (<1)
  Serious AE 15 (9) 6 (4) 15 (9) 13 (8) 17 (10)
  AE leading to withdrawal (excluding 
RA ﬂ  are)
2 (1) 2 (1) 3 (2) 3 (2) 7 (4)
IRR (any)*
  Day 1 infusion  24 (14) 31 (19) 42 (25) 19 (13)† 17 (11)†
  Day 15 infusion 14 (8) 12 (7) 10 (6) 6 (4)† 8 (5)†
  IRR leading to withdrawal 0 (0) 0 (0) 1 (1) 0 (0) 2 (1)
Infection
  Any 74 (43) 69 (41) 61 (36) 96 (57) 85 (50)
  Serious‡ 4 (2) 1 (<1) 2 (1) 3 (2) 3 (2)
Lower gastrointestinal events
  Any 20 (12) 16 (10) 16 (9) 21 (13) 24 (14)
  Serious 3 (2) 1 (1) 1 (<1) 2 (1) 1 (<1)
Cardiac disorder events
  Any 4 (2) 5 (3) 7 (4) 8 (5) 8 (5)
  Serious 2 (1) 2 (1) 1 (<1) 2 (1) 1 (<1)
Vascular disorder events
  Any 4 (2) 6 (4) 7 (4) 11 (7) 8 (5)
 Serious 0 0 0 0 0
  Malignancy 1 (<1) 1 (<1) 2 (1) 1 (<1) 2 (1)
AE rates per 100 patient-years (95% CI)
  Overall infection rate 159.00 (133.53 to 189.34) 138.13 (114.59 to 166.52) 120.45 (98.81 to 146.82) 133.83 (116.67 to 153.52) 106.94 (91.76 to 124.63)
  Serious infection‡ rate 8.83 (4.21 to 18.53) 1.26 (0.18 to 8.92) 2.46 (0.61 to 9.83) 2.62 (0.98 to 6.99) 1.96 (0.63 to 6.07)
*AEs occurring during or within 24 h of an infusion and considered by the investigator to have at least a possible relation to treatment.
†Week 24 to week 48, based on number of patients receiving the infusion/day.
‡Reported as serious and/or treated with intravenous antibiotics.
AE, adverse event; IRR, infusion-related reaction; RA, rheumatoid arthritis; SAE, serious adverse event.
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with 2.62 and 1.96 serious infections per 100 patient-years 
observed for rituximab 2×500 mg and 2×1000 mg doses, 
respectively.
Two deaths (interstitial lung disease and abdominal sepsis) 
occurred between weeks 24 and 48 in patients who had received 
rituximab 2×500 mg + MTX; the former death was preceded 
by a serious infection. In addition three deaths occurred (ven-
tricular asystole, cardiac failure and pancreatic carcinoma), one 
in each treatment arm, in patients who had withdrawn due to 
serious events prior to week 24 and subsequently died within 
the 48-week period.
DISCUSSION
The results of this study demonstrate that treatment with 
  rituximab is associated with signiﬁ  cant improvements in clinical 
outcomes in patients with RA with an inadequate response to 
MTX and who have not been previously treated with biological 
DMARDs. Signiﬁ  cantly higher proportions of patients achieved 
the primary end point (ACR20) and this was supported by sig-
niﬁ  cant improvements in the majority of secondary measures 
including change in DAS28-ESR, EULAR and ACR50 responses, 
DAS28-ESR LDA and remission. There were also statistically 
signiﬁ   cant and clinically important improvements in physi-
cal function, as indicated by the HAQ-DI end points, and in 
FACIT-F and SF-36. These data are consistent with previously 
reported studies showing clinical improvement with rituximab 
in patients with an inadequate response to DMARDs or TNF 
inhibitors.1–3
In contrast to previous studies,1–3 this study was conducted 
over a longer observation period (48 weeks vs 24 weeks) and 
included a second course of rituximab. Using a repeat treatment 
criterion based on targeting DAS28-ESR remission, the major-
ity of patients (90%) received a second course between weeks 
24 and 48, with the majority of these given at 24–30 weeks. In 
rituximab-treated patients, efﬁ  cacy outcomes at week 48 were 
comparable to those at week 24; additionally, improvement was 
observed for several clinically important end points, including 
an approximate doubling in the proportion of patients achiev-
ing LDA in the rituximab (2×1000 mg) + MTX dose group from 
week 24 to week 48 (table 3).
The current study continued to explore the effect of two dos-
ing regimens of rituximab, 2×500 mg and 2×1000 mg. Although 
a previous study,9 suggested higher levels of efﬁ  cacy (ACR70, 
EULAR good response and DAS28-ESR LDA) in patients receiv-
ing rituximab 2×1000 mg, the results of the current study do 
not appear to suggest any clinical difference between the doses, 
either at 24 or 48 weeks. Recent data in patients with early RA 
have also shown similar clinical responses for both rituximab 
doses; however, only the 2×1000 mg dose signiﬁ  cantly slowed 
progression of joint damage.10 Therefore, despite similar clini-
cal outcomes, the absolute requirement to also prevent joint 
damage would suggest that rituximab 2×1000 mg is the optimal 
therapeutic dose.
A consistent treatment effect for both rituximab groups com-
pared with placebo was observed at week 24 across several clini-
cally relevant subgroups, including baseline autoantibody status. 
This ﬁ  nding is in contrast to the more pronounced effect in 
patients who were RF/anti-CCP seropositive observed in a pre-
vious study.11 However, the superior response of patients who 
were seropositive strengthened over time, as shown by greater 
decreases in disease activity and enhanced ACR responses at 
week 48 in rituximab-treated patients who were seropositive 
compared with patients who were seronegative.
The safety proﬁ  le observed in this study is also consistent 
with that of previous short-term and long-term observations of 
rituximab in patients with RA.2 3 12 As previously reported, IRRs 
are a primary safety concern, with the incidence highest during 
the ﬁ  rst infusion of the ﬁ  rst course. This was most evident in 
patients treated with rituximab (2×1000 mg) + MTX; however, 
the second infusion of the ﬁ  rst course and both infusions of the 
second course had IRR rates that were lower than the IRR rate 
of the initial infusion and were comparable between rituximab 
doses. Irrespective of course or rituximab dose, there were no 
serious IRRs reported; however, three patients receiving ritux-
imab (2×1000 mg) + MTX discontinued treatment due to IRRs.
Infections, particularly serious infections, remain a concern 
with all biological treatments for RA. Encouragingly, the rate 
of infection observed in patients receiving rituximab + MTX 
was low and comparable to patients receiving MTX alone over 
the placebo-controlled 24-week period. This low rate of serious 
infection continued throughout the full 48-week period, with 
no obvious difference between the rituximab doses.
Although reductions in Ig levels (predominantly IgM) were 
observed, mean Ig levels stayed within normal limits, and there 
did not appear to be any association between reduced Ig con-
centrations and infection.
The incidence of other events of interest, including malignan-
cies and cardiac, vascular or lower gastrointestinal events did 
not indicate higher rates of such events with rituximab + MTX 
compared with MTX alone.
Both doses of rituximab were associated with rapid and com-
plete depletion of peripheral CD19+ B cells, with depletion 
and repletion patterns as previously observed.3 The incidence 
of immunogenicity (HACAs) was also comparable with previ-
ous results with no evidence that HACA formation altered the 
therapeutic or safety proﬁ  le of rituximab.12
In conclusion, the results of this study conﬁ  rm that rituximab 
is an effective and well tolerated preferred biological treat-
ment for patients with active RA and an inadequate response 
to MTX.
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